Search

Jeffrey R Shearstone

age ~51

from Framingham, MA

Get Report
Also known as:
  • Jeffrey Richard Shearstone
  • Jeff R Shearstone
  • Jeffery R Shearstone
  • Richard Shearstone
  • Jeffrey R Jacobs
  • Jrichard Shearstone
  • Dick Shearstone
  • Rick Shearstone
  • Jeff Shearston
Related to:
Connected to:

Jeffrey Shearstone Phones & Addresses

  • Framingham, MA
  • Brookline, MA
  • Westborough, MA
  • Cambridge, MA
  • Taunton, MA
  • Camarillo, CA
  • Seattle, WA
  • Newbury Park, CA
  • 21 Chouteau Ave, Framingham, MA 01701

Us Patents

  • Method For Preparing Limiting Quantities Of Nucleic Acids

    view source
  • US Patent:
    20070092904, Apr 26, 2007
  • Filed:
    Oct 16, 2006
  • Appl. No.:
    11/581077
  • Inventors:
    Jeffrey Shearstone - Cambridge MA, US
  • Assignee:
    Biogen Idec MA Inc. - Cambridge MA
  • International Classification:
    C12Q 1/68
    C12P 19/34
  • US Classification:
    435006000, 435091200
  • Abstract:
    The present invention relates generally to the amplification of nucleic acids. More specifically, the present invention facilitates amplification of total RNA for a variety of purposes, including analysis utilizing nucleotide assays, constructing cDNA libraries, in situ hybridization, and TaqMan. Additionally, the present invention facilitates amplification of total RNA isolated from biological tissues.

  • Compositions And Methods For Treating Sickle Cell Disease

    view source
  • US Patent:
    20220401489, Dec 22, 2022
  • Filed:
    Nov 6, 2020
  • Appl. No.:
    17/774779
  • Inventors:
    - Cambridge MA, US
    Jeffrey R. Shearstone - Framingham MA, US
  • International Classification:
    A61K 35/28
    A61K 9/00
  • Abstract:
    The present invention features compositions and methods useful in inhibiting the expression of NFIX within a cell and thereby treating patients suffering from a hemoglobinopathy such as sickle cell disease or β-thalassemia

  • Increasing Expression Of Interferon Regulated Genes With Combinatons Of Histone Deacetylase Inhibitors And Immunomodulatory Drugs

    view source
  • US Patent:
    20220288066, Sep 15, 2022
  • Filed:
    Mar 22, 2022
  • Appl. No.:
    17/701222
  • Inventors:
    - Summit NJ, US
    Jeffrey R. Shearstone - Framingham MA, US
  • Assignee:
    ACETYLON PHARMACEUTICALS, INC. - Summit NJ
  • International Classification:
    A61K 31/505
    A61K 31/454
    A61P 35/00
  • Abstract:
    Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.

  • Increasing Expression Of Interferon Regulated Genes With Combinatons Of Histone Deacetylase Inhibitors And Immunomodulatory Drugs

    view source
  • US Patent:
    20190046529, Feb 14, 2019
  • Filed:
    Feb 17, 2017
  • Appl. No.:
    16/076590
  • Inventors:
    - Summit NJ, US
    Jeffrey R. Shearstone - Framingham MA, US
  • International Classification:
    A61K 31/505
    A61K 31/454
    A61P 35/00
  • Abstract:
    Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.
Get Report for Jeffrey R Shearstone from Framingham, MA, age ~51
Control profile